Table 1.
Time to Benefit for Lung Cancer Screening at Specific Thresholds of Absolute Risk Reduction.
| Trial (publication) | Time to benefit in years (95% CI) | ||
|---|---|---|---|
| ARR=0.0005a | ARR=0.001b | ARR=0.002c | |
| LUSI (Becker 2020) | 0.7 (0.2, 12.0)d | 1.3 (0.3, 12.0)d | 2.8 (0.8, 12.0)d |
| UKLS (Field 2021) | 1.0 (0.2, 8.4) | 1.6 (0.3, 12.0)d | 2.7 (0.8, 12.0)d |
| NELSON (De Koning 2020) | 2.3 (1.3, 6.3) | 3.3 (1.9, 7.3) | 4.8 (3.1, 9.3) |
| DANTE (Infante 2015) | 0.4 (0.1, 12.0)d | 1.1 (0.2, 12.0)d | 12.0 (0.3, 12.0)d |
| NLST (NLST 2019) | 1.5 (0.8, 4.5) | 2.7 (1.7, 12.0)d | 5.1 (2.9, 12.0)d |
| ITALUNG (Paci 2017) | 4.9 (0.8, 11.3) | 5.3 (1.3, 11.6) | 6.0 (2.3, 12.0)d |
| MILD (Pastorino 2019) | 4.2 (0.7, 11.8) | 4.8 (1.3, 12.0)d | 5.8 (2.1, 12.0)d |
| DLCST (Wille 2016) | 12.0 (1.3, 12.0)d | 12.0 (2.5, 12.0)d | 12.0 (4.6, 12.0)d |
| Summary | 2.2 (1.4, 3.4) | 3.4 (2.2, 5.1) | 5.2 (3.7, 7.3) |
Note: Boldface indicates statistical significance (p<0.001). NLST results were derived using individual data from the original dataset.
ARR, absolute risk reduction; NA, not applicable.
a
Time to prevent 1 lung cancer death per 2000 people screened with LDCT.
b
Time to prevent 1 lung cancer death per 1000 people screened with LDCT.
c
Time to prevent 1 lung cancer death per 500 people screened with LDCT.
d
The upper limit of 95% CI does not exceed 12.0 years due to censoring at 12 years of follow-up.